Among them, immune checkpoint inhibitors, which target PD-1, PD-L1, and CTLA-4, are increasingly used for certain cancers; however, this increased use has resulted in increased reports of immune-related adverse events (irAEs). This evidence concerns the gene PDCD1 and cancer.